This article is more than 5 years old. Information may no longer be current.
US Interventional Cardiology Market Forecast: Decline Expected Through 2016
Click Here to Manage Email Alerts
Millennium Research Group, market researcher for the medical technology market, has predicted that interventional cardiology devices will diminish in sales by an average of 3% per year through 2016 due to maturity in procedures and heavy downward pressures on sales prices.
Despite this, the report also stated that the market will be worth more than $2.4 billion in 2016, allowing for continued competition and market innovation.
According to Ian Swanson, analyst for Millennium Research Group, PCI in the United States is no longer seeing the strong growth of previous years, partly due to the decline in the insured population after the economic downturn and people subsequently putting off visits to doctors.
“In addition, there has been increased scrutiny on practices of over-stenting, with a resulting increase in the use of intravascular imaging techniques to identify cases where stenting is truly necessary. This will help drive sales of intravascular imaging devices and pressure guidewires,” Swanson said in an accompanying press release, adding that IVUS and optional coherence tomography catheters and fractional flow reserve guidewires are all providing additional information that enables more considered decisions about stent appropriateness, and will inevitably lead to fewer stent procedures.
Perspective
Back to Top
David J. Cohen, MD
I would tend to agree with the general assessment of this market research, although I wouldn’t be so confident as to try to quantify it. The combination of increasing understanding of the true value of PCI procedures (highest in ACS, lower in chronic/stable coronary disease), improved secondary coronary prevention (generic statins, more potent antiplatelet agents, policies reducing rates of smoking) have led to general decreases in PCI volumes over the last 4 to 5 years. In the future, more widespread availability and acceptance of tools that can help to determine the presence or absence of myocardial ischemia beyond simple visual estimation should enable further targeting of PCI (at least in the setting of chronic/stable CAD) to the most appropriate patients and lesions, which may lead to further erosions in volumes.
Click Here to Manage Email Alerts